2024 journal article
Toxicology study of a tissue anchoring paclitaxel prodrug
BMC PHARMACOLOGY & TOXICOLOGY, 25(1).
author keywords: Tissue-Reactive Anchoring Pharmaceuticals (TRAPs); Paclitaxel; Drug delivery; Cremophor; Local chemotherapy
UN Sustainable Development Goal Categories
3. Good Health and Well-being
(OpenAlex)
Source: Web Of Science
Added: December 16, 2024
Abstract Background Local drug presentation made possible by drug-eluting depots provides benefits for a vast array of diseases, including cancer, microbial infection, and wound healing. Drug-eluting depots provide sustained drug release of therapeutics directly at disease sites with tunable kinetics, remove the need for drugs to access disease sites from circulation, and reduce the side effects associated with systemic therapy. Recently, we introduced an entirely novel approach to local drug presentation named Tissue-Reactive Anchoring Pharmaceuticals (TRAPs). TRAPs enables local drug presentation without any material carriers, capitalizing on innate tissue structures to anchor drugs at the site of administration. Methods In this report, we comprehensively evaluate the local and systemic toxicological profile of a paclitaxel version of TRAPs in mice by clinical observations, body weight monitoring, histopathological evaluations of injection sites and major organs, as well as blood and urine analyses. Results We find that intradermal administration of TRAP-paclitaxel does not induce substantial toxic effects. Localized inflammatory responses were observed at the injection sites and secondary minimal, non-specific inflammation was observed in the liver. All other organs displayed unremarkable histological findings. Conclusions These findings support the potential of TRAP-paclitaxel as a promising candidate for localized cancer treatment, offering high-concentration drug delivery while mitigating scarring and adverse side effects.